# PALMIGES





PEA 300 mg, Genistein 4 mg, Daidzein 50 mg Capsules

# **Description:**

- PALMIGES counters the condition of Inflammation in Neuropathic Pain resulting in lowering/alleviating the symptoms of chronic Pain.
- PALMIGES is a composed of PEA, Genistein and Daidzein manufactured in accordance with MPFAITECH technology.
- RITALA is the proprietary blend & is manufactured in Technical Collaboration with ENAVANT Research LLC, USA.
- RITALA and MPFAITECH are the Registered Trademarks of Enavant Research LLC. USA.

#### **Indications:**

- Chronic Pain
- Neuropathic Pain
- Diabetic Neuropathy
- Sciatic Pain & Nerve compression pain
- Fibromyalgia
- Trigeminal Neuralgia
- Migraine

# PALMIGES contains the following components:

Palmitoylethanolamide (PEA)	<ul> <li>Palmitoylethanolamide (PEA) is considered an endogenous PPAR- agonist or activator, interacting with this receptor to inhibit inflammatory pathways &amp; oxidative stress.</li> <li>During chronic pain, PEA can modulate the PPAR pathway that is able to attenuate NFkB induced inflammatory factors (IL-1, or TNF), inhibit infiltration and activation of MC, reduce mesangial matrix proliferation induced by reactive oxidative stress (ROS) which then resulted in albuminuria.</li> </ul>
Genistein	• Genistein, is an FAAH Inhibitor that prevents the degradation of PEA from FAAH enzyme in the body & also exert synergistic effect with PEA to reduce oxidative stress in the over-inflamed neuronal cells.
Daidzein	• Daidzein belongs to the class of isoflavones and serves as a potent FAAH Inhibitor in conjunction with Genistein. It works as a competitive binder to FAAH disallowing it to degrade the externally supplemented PEA.
MPFAITECH	• A Technology to ensure the proprietary blend is presented in a form that could be easily absorbed in the human body.

### Dosage:

- Standard recommended daily dose of Palmiges is 1-2 capsules preferably divided over the day
- Or as prescribed by Medical Practitioner

#### References:

- 1. J Indian Prosthodont Soc. 2016 Apr-Jun; 16(2): 114-115
- 2. The journal of Pain, june 2017.

## **Frimline Private Limited**

Phone: +91-79-6616-8999 | Email: info@frimline.com | www.frimline.com

I am:		
Call me on:_		
Mail ma @ ·		

@2020 All rights reserved, Frimline Private Limited